Enanta Pharmaceuticals is a research and development-focused biotechnology company situated in United States which uses its powerful chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Their research and development mainly focuses on three disease targets:
1. Hepatitis B Virus (HBV)
2. PBC and Respiratory Syncytial Virus (RSV)
3. Non-alcoholic Steatohepatitis (NASH).
Enanta has found a novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes which was designed for use against the hepatitis C virus (HCV).
The main Vision
The main objective of this company is to do research in the field of liver diseases and viral infections.The research and development has mainly focused biotechnology companies who are using powerful chemistry-driven approaches .
The company has discovered novel protease inhibitors which are members of the direct-acting-antiviral (DAA) inhibitor classes designed to use against the hepatitis C virus (HCV). t
Enanta has discovered EDP-305, an FXR agonist product candidate for NASH and PBC, currently in Phase 1 clinical development, and has identified a clinical candidate for RSV, EDP-938, now, in preclinical development.
Enanta is also developing early lead candidates for HBV